Matisse Capital’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Matisse Capital’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24,803	Closed	-$687K	–	122
2022 Q2	$687K	Sell	24,803 -44,000	-64%	-$1.25M	0.65%	53
2022 Q1	$2.31M	Sell	68,803 -73,241	-52%	-$2.54M	2.13%	9
2021 Q4	$6M	Buy	142,044 +134,500	+1,783%	+$5.99M	4.15%	4
2021 Q3	$343K	Hold	7,544	–	–	0.13%	123
2021 Q2	$369K	Buy	7,544 +104	+1%	+$4.98K	0.12%	115
2021 Q1	$373K	Hold	7,440	–	–	0.11%	131
2020 Q4	$381K	Hold	7,440	–	–	0.12%	119
2020 Q3	$306K	Hold	7,440	–	–	0.12%	107
2020 Q2	$311K	Buy	+7,440	New	+$294K	0.1%	117

Other funds holding SBIO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

ASB Consultores Aventura, Florida $30.1M AUM 22.96% 1-Year Est. Return

Matisse Capital's SBIO Position: Q3 2022 in Review

Matisse Capital sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q3 2022, closing a stake of 24,803 shares — an estimated $687K sold.

Matisse Capital first reported a position in SBIO in Q2 2020 and held it in 9 quarters. The position peaked at $6M in Q4 2021. 44 funds tracked by Wall St. Rank hold SBIO as of Q3 2022.

Matisse Capital reported no remaining ALPS Medical Breakthroughs ETF position as of Q3 2022 after selling out during the quarter.
Matisse Capital sold 24,803 ALPS Medical Breakthroughs ETF shares in Q3 2022, an estimated $687K.
Matisse Capital first reported a position in ALPS Medical Breakthroughs ETF in Q2 2020 and held it in 9 quarters.
Matisse Capital's ALPS Medical Breakthroughs ETF position peaked at $6M in Q4 2021.
44 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2022.

Based on Matisse Capital's 13F filing for Q3 2022, filed 8 Nov 2022.